{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:10:08Z","timestamp":1792703408039,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"crossref","award":["Projects of Relevant National Interest (PRIN) number 2020RRJP5L_005 and number 2017E5L5P3_004"],"award-info":[{"award-number":["Projects of Relevant National Interest (PRIN) number 2020RRJP5L_005 and number 2017E5L5P3_004"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47488-5","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T19:06:32Z","timestamp":1775761592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Deruxtecan-based antibody\u2013drug-conjugates induce senescence in HER2-positive breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Elena","family":"Vezzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Pinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Galbiati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Zambroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Dall\u2019Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Galbardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeno","family":"Lavagnino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scielzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-1078","authenticated-orcid":false,"given":"Tiziana","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"47488_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","volume":"381","author":"DF Hayes","year":"2019","unstructured":"Hayes, D. F. HER2 and breast cancer - A phenomenal success story. N. Engl. J. Med. 381, 1284\u20131286 (2019).","journal-title":"N. Engl. J. Med."},{"key":"47488_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25\u201332 (2012).","journal-title":"Lancet Oncol."},{"key":"47488_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380, 617\u2013628 (2019).","journal-title":"N. Engl. J. Med."},{"key":"47488_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-021-00377-8","volume":"8","author":"L Gianni","year":"2022","unstructured":"Gianni, L. et al. Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. NPJ Breast Cancer 8, 1 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"47488_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211006960","volume":"13","author":"F Ligorio","year":"2021","unstructured":"Ligorio, F. et al. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. Ther. Adv. Med. Oncol. 13, 17588359211006960 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"47488_CR6","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1158\/1078-0432.CCR-21-3185","volume":"28","author":"L Vigan\u00f2","year":"2022","unstructured":"Vigan\u00f2, L. et al. Modulation of the Estrogen\/erbB2 receptors cross-talk by CDK4\/6 inhibition triggers sustained senescence in Estrogen Receptor- and ErbB2-positive breast cancer. Clin. Cancer Res. 28, 2167\u20132179 (2022).","journal-title":"Clin. Cancer Res."},{"key":"47488_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104389","volume":"199","author":"OH Rodr\u00edguez-Bejarano","year":"2024","unstructured":"Rodr\u00edguez-Bejarano, O. H., Parra-L\u00f3pez, C. & Patarroyo, M. A. A review concerning the breast cancer-related tumour microenvironment. Crit. Rev. Oncol. Hematol. 199, 104389 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"47488_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040800","author":"BS Zimmerman","year":"2024","unstructured":"Zimmerman, B. S. & Esteva, F. J. Next-generation HER2-targeted antibody-drug conjugates in breast cancer. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers16040800 (2024).","journal-title":"Cancers (Basel)"},{"key":"47488_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104355","volume":"198","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn, M. et al. Trastuzumab deruxtecan in breast cancer. Crit. Rev. Oncol. Hematol. 198, 104355 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"47488_CR10","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck, N. et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b\/4 trial. Nat. Med. 30, 3717\u20133727 (2024).","journal-title":"Nat. Med."},{"key":"47488_CR11","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer. N. Engl. J. Med. 391, 2110\u20132122 (2024).","journal-title":"N. Engl. J. Med."},{"key":"47488_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-OT1-02-03","volume":"82","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer, C. E. Jr. et al. Abstract OT1-02-03: Trastuzumab Deruxtecan (T-DXd; DS-8201) vs Trastuzumab Emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05). Cancer Res. 82, OT1-02\u201303 (2022).","journal-title":"Cancer Res."},{"key":"47488_CR13","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1158\/1538-7445.AM2024-5857","volume":"84","author":"MB Nilsson","year":"2024","unstructured":"Nilsson, M. B. et al. Abstract 5857: Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained. Cancer Res. 84, 5857\u20135857 (2024).","journal-title":"Cancer Res."},{"key":"47488_CR14","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial. Nat. Med. 29, 2110\u20132120 (2023).","journal-title":"Nat. Med."},{"key":"47488_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0647","author":"W Chen","year":"2025","unstructured":"Chen, W. et al. Trastuzumab Deruxtecan (T-DXd) resistance via loss of HER2 expression and binding. Cancer Discov https:\/\/doi.org\/10.1158\/2159-8290.CD-25-0647 (2025).","journal-title":"Cancer Discov"},{"key":"47488_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327\u2013344 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"47488_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13046-017-0615-0","volume":"36","author":"C D\u2019Alesio","year":"2017","unstructured":"D\u2019Alesio, C. et al. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2(+) breast cancer cells. J. Exp. Clin. Cancer Res. 36, 154 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"47488_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10637-005-2899-8","volume":"23","author":"CH Yeon","year":"2005","unstructured":"Yeon, C. H. & Pegram, M. D. Anti-erbB-2 antibody Trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs 23, 391\u2013409 (2005).","journal-title":"Invest. New Drugs"},{"key":"47488_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.639572","volume":"12","author":"FV Sbrana","year":"2021","unstructured":"Sbrana, F. V. et al. 3D bioprinting allows the establishment of long-term 3D culture model for chronic lymphocytic leukemia cells. Front. Immunol. 12, 639572 (2021).","journal-title":"Front. Immunol."},{"key":"47488_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55\u201363 (1983).","journal-title":"J. Immunol. Methods"},{"key":"47488_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/acel.12592","volume":"16","author":"A Biran","year":"2017","unstructured":"Biran, A. et al. Quantitative identification of senescent cells in aging and disease. Aging Cell 16, 661\u2013671 (2017).","journal-title":"Aging Cell"},{"key":"47488_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-030-00934-2_30","volume-title":"Medical Image Computing and Computer Assisted Intervention \u2013 MICCAI 2018","author":"U Schmidt","year":"2018","unstructured":"Schmidt, U., Weigert, M., Broaddus, C. & Myers, G. Cell Detection with Star-Convex Polygons. In Medical Image Computing and Computer Assisted Intervention \u2013 MICCAI 2018 (eds Frangi, A. F. et al.) 265\u2013273 (Springer International Publishing, 2018)."},{"key":"47488_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01504-21","volume":"10","author":"C Fenizia","year":"2022","unstructured":"Fenizia, C. et al. Cyclosporine A inhibits viral infection and release as well as cytokine production in lung cells by three SARS-CoV-2 variants. Microbiol. Spectr. 10, e0150421 (2022).","journal-title":"Microbiol. Spectr."},{"key":"47488_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv020","volume":"107","author":"MF Zacarias-Fluck","year":"2015","unstructured":"Zacarias-Fluck, M. F. et al. Effect of cellular senescence on the growth of HER2-positive breast cancers. J. Natl. Cancer Inst. 107, djv020 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"47488_CR25","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc2716","volume":"9","author":"DW Meek","year":"2009","unstructured":"Meek, D. W. Tumour suppression by p53: A role for the DNA damage response?. Nat. Rev. Cancer 9, 714\u2013723 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"47488_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis, V. et al. Cellular senescence: Defining a path forward. Cell 179, 813\u2013827 (2019).","journal-title":"Cell"},{"key":"47488_CR27","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202357265","volume":"24","author":"JX Tan","year":"2023","unstructured":"Tan, J. X. & Finkel, T. Lysosomes in senescence and aging. EMBO Rep. 24, e57265 (2023).","journal-title":"EMBO Rep."},{"key":"47488_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.arr.2018.08.003","volume":"47","author":"JT Park","year":"2018","unstructured":"Park, J. T., Lee, Y.-S., Cho, K. A. & Park, S. C. Adjustment of the lysosomal-mitochondrial axis for control of cellular senescence. Ageing Res. Rev. 47, 176\u2013182 (2018).","journal-title":"Ageing Res. Rev."},{"key":"47488_CR29","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/febs.16381","volume":"290","author":"M Takasugi","year":"2023","unstructured":"Takasugi, M., Yoshida, Y., Hara, E. & Ohtani, N. The role of cellular senescence and SASP in tumour microenvironment. FEBS J. 290, 1348\u20131361 (2023).","journal-title":"FEBS J."},{"key":"47488_CR30","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/febs.16361","volume":"290","author":"H Martini","year":"2023","unstructured":"Martini, H. & Passos, J. F. Cellular senescence: All roads lead to mitochondria. FEBS J. 290, 1186\u20131202 (2023).","journal-title":"FEBS J."},{"key":"47488_CR31","doi-asserted-by":"publisher","first-page":"e158447","DOI":"10.1172\/JCI158447","volume":"132","author":"S Miwa","year":"2022","unstructured":"Miwa, S., Kashyap, S., von Chini, E. & Zglinicki, T. Mitochondrial dysfunction in cell senescence and aging. J. Clin. Invest. 132, e158447 (2022).","journal-title":"J. Clin. Invest."},{"key":"47488_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1268275","volume":"11","author":"RK Jha","year":"2023","unstructured":"Jha, R. K., Kouzine, F. & Levens, D. MYC function and regulation in physiological perspective. Front. Cell Dev. Biol. 11, 1268275 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"47488_CR33","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1158\/0008-5472.CAN-22-2948","volume":"83","author":"P Lin","year":"2023","unstructured":"Lin, P. et al. Topoisomerase 1 inhibition in MYC-driven cancer promotes aberrant R-Loop accumulation to induce synthetic lethality. Cancer Res. 83, 4015\u20134029 (2023).","journal-title":"Cancer Res."},{"key":"47488_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham, S. A. et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 534, 341\u2013346 (2016).","journal-title":"Nature"},{"key":"47488_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2013.08.032","volume":"155","author":"S Cogliati","year":"2013","unstructured":"Cogliati, S. et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell 155, 160\u2013171 (2013).","journal-title":"Cell"},{"key":"47488_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.tibs.2016.01.001","volume":"41","author":"S Cogliati","year":"2016","unstructured":"Cogliati, S., Enriquez, J. A. & Scorrano, L. Mitochondrial cristae: Where beauty meets functionality. Trends Biochem. Sci. 41, 261\u2013273 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"47488_CR37","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"L-C Tsao","year":"2025","unstructured":"Tsao, L.-C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 (2025).","journal-title":"Nat. Commun."},{"key":"47488_CR38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/acel.12518","volume":"15","author":"NV Petrova","year":"2016","unstructured":"Petrova, N. V., Velichko, A. K., Razin, S. V. & Kantidze, O. L. Small molecule compounds that induce cellular senescence. Aging Cell 15, 999\u20131017 (2016).","journal-title":"Aging Cell"},{"key":"47488_CR39","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022111241","volume":"42","author":"R Curnock","year":"2023","unstructured":"Curnock, R. et al. TFEB-dependent lysosome biogenesis is required for senescence. EMBO J. 42, e111241 (2023).","journal-title":"EMBO J."},{"key":"47488_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.645593","volume":"9","author":"R Kumari","year":"2021","unstructured":"Kumari, R. & Jat, P. Mechanisms of cellular senescence: Cell cycle arrest and senescence associated secretory phenotype. Front. Cell Dev. Biol. 9, 645593 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"47488_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"J-P Copp\u00e9","year":"2010","unstructured":"Copp\u00e9, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: The dark side of tumor suppression. Annu. Rev. Pathol. 5, 99\u2013118 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"47488_CR42","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.devcel.2023.05.010","volume":"58","author":"M D\u2019Ambrosio","year":"2023","unstructured":"D\u2019Ambrosio, M. & Gil, J. Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies. Dev. Cell 58, 1007\u20131021 (2023).","journal-title":"Dev. Cell"},{"key":"47488_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cells13151281","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Lomeli, I. & Kron, S. J. Therapy-induced cellular senescence: Potentiating tumor elimination or driving cancer resistance and recurrence?. Cells https:\/\/doi.org\/10.3390\/cells13151281 (2024).","journal-title":"Cells"},{"key":"47488_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41392-022-01151-3","volume":"7","author":"X Li","year":"2022","unstructured":"Li, X. et al. Lactate metabolism in human health and disease. Signal Transduct. Target. Ther. 7, 305 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"47488_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.519","volume":"5","author":"Y Yu","year":"2024","unstructured":"Yu, Y. et al. Roles of reactive oxygen species in inflammation and cancer. MedComm 5, e519 (2024).","journal-title":"MedComm"},{"key":"47488_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01893-3","volume":"22","author":"K-S Oh","year":"2024","unstructured":"Oh, K.-S. et al. Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells. Cell Commun. Signal. 22, 518 (2024).","journal-title":"Cell Commun. Signal."},{"key":"47488_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094774","author":"A Indini","year":"2021","unstructured":"Indini, A., Rijavec, E. & Grossi, F. Trastuzumab Deruxtecan: Changing the destiny of HER2 expressing solid tumors. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22094774 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"47488_CR48","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: Results from the Phase I TROPION-PanTumor01 study. J. Clin. Oncol. 42, 2281\u20132294 (2024).","journal-title":"J. Clin. Oncol."},{"key":"47488_CR49","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2217\/fon-2023-0228","volume":"19","author":"RA Dent","year":"2023","unstructured":"Dent, R. A. et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 19, 2349\u20132359 (2023).","journal-title":"Future Oncol."},{"key":"47488_CR50","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: Lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"47488_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104470","volume":"81","author":"X Peng","year":"2025","unstructured":"Peng, X. et al. The ideal strategies of antibody-drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study. Breast 81, 104470 (2025).","journal-title":"Breast"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47488-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47488-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47488-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:01:57Z","timestamp":1779670917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47488-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47488"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47488-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"GB reports fees for advisory boards, travel grants, consultancy: Seagen, Eli Lilly, Novartis, Pfizer, Roche, AstraZeneca, MSD, Daiichi Sankyio, Eisai, Gilead, Exact Science, Stemline, Agendia, but declares no non-financial competing interests. All the competing interests were outside the submitted work. All other authors declare no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16106"}}